S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
- PMID: 9014201
- DOI: 10.1097/00008571-199612000-00005
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
Abstract
The polymorphic metabolism of S-mephenytoin and the distribution of two known deleterious mutant CYP2C19 alleles was determined among 114 healthy unrelated black Ethiopians. Six subjects (5.2%) were poor metabolizers (PMs) of S-mephenytoin. The frequencies of the defective CYP2C19*2 (CYP2C19m1) and CYP2C19*3 (CYP2C19m2) alleles were 0.14 and 0.02, respectively. Three of the PMs were homozygous for the CYP2C19*2 allele and the remaining three PMs were heterozygous for both the CYP2C19*2 and CYP2C19*3 mutant alleles. It is concluded that the frequency of PMs for S-mephenytoin is similar in Ethiopians, Zimbabweans and Caucasians and that the CYP2C19*3 allele, for the first time identified in a black population, together with the CYP2C19*2 allele account for all of the defective CYP2C19 alleles among the Ethiopian PMs.
Similar articles
-
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.Pharmacogenetics. 1995 Dec;5(6):358-63. doi: 10.1097/00008571-199512000-00004. Pharmacogenetics. 1995. PMID: 8747407
-
CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.Eur J Clin Pharmacol. 2002 Apr;58(1):15-8. doi: 10.1007/s00228-002-0425-x. Epub 2002 Feb 22. Eur J Clin Pharmacol. 2002. PMID: 11956668 Clinical Trial.
-
Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.Pharmacogenetics. 1996 Jun;6(3):265-7. doi: 10.1097/00008571-199606000-00011. Pharmacogenetics. 1996. PMID: 8807668
-
Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005. Clin Pharmacokinet. 1995. PMID: 8521680 Review.
-
CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.Clin Chim Acta. 2001 Nov;313(1-2):203-8. doi: 10.1016/s0009-8981(01)00696-9. Clin Chim Acta. 2001. PMID: 11694260 Review.
Cited by
-
The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.Molecules. 2012 Jan 12;17(1):688-702. doi: 10.3390/molecules17010688. Molecules. 2012. PMID: 22241465 Free PMC article. Clinical Trial.
-
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.Br J Clin Pharmacol. 2007 Jul;64(1):67-74. doi: 10.1111/j.1365-2125.2007.02846.x. Epub 2007 Feb 12. Br J Clin Pharmacol. 2007. PMID: 17298483 Free PMC article.
-
Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Br J Clin Pharmacol. 1999 Sep;48(3):402-8. doi: 10.1046/j.1365-2125.1999.00009.x. Br J Clin Pharmacol. 1999. PMID: 10510153 Free PMC article.
-
Genotype‑phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy.Mol Med Rep. 2016 Mar;13(3):2117-23. doi: 10.3892/mmr.2016.4776. Epub 2016 Jan 13. Mol Med Rep. 2016. PMID: 26781306 Free PMC article.
-
Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.J Genet. 2015 Dec;94(4):765-70. doi: 10.1007/s12041-015-0581-2. J Genet. 2015. PMID: 26690534 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources